Paliperidone Induced Hypoglycemia by Increasing Insulin Secretion

Omi, Tsubasa; Riku, Keisen; Fukumoto, Motoyuki; Kanai, Koji; Omura, Yumi; Takada, Hiromune; Matunaga, Hidenori

doi:10.1155/2016/1805414

Cited by 6 publications

(5 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The acute and chronic treatment with paliperidone did not alter serum insulin levels and β-cell function with the homeostatic model assessment (HOMA-B) (207,313,321). However, a case report showed increased insulin secretion, causing hypoglycemia in a schizophrenic female patient (322).…”

Section: Paliperidonementioning

confidence: 93%

Immunoendocrine Peripheral Effects Induced by Atypical Antipsychotics

et al. 2020

View full text Add to dashboard Cite

Atypical antipsychotics (AAP) or second-generation antipsychotics are the clinical option for schizophrenia treatment during acute psychoses, but they are also indicated for maintenance during lifetime, even though they are being used for other psychiatric conditions in clinical practice such as affective disorders and autism spectrum disorder, among others. These drugs are differentiated from typical antipsychotics based on their clinical profile and are a better choice because they cause fewer side effects regarding extrapyramidal symptoms (EPS). Even though they provide clear therapeutic benefits, AAP induce peripheral effects that trigger phenotypic, functional, and systemic changes outside the Central Nervous System (CNS). Metabolic disease is frequently associated with AAP and significantly impacts the patient's quality of life. However, other peripheral changes of clinical relevance are present during AAP treatment, such as alterations in the immune and endocrine systems as well as the intestinal microbiome. These less studied alterations also have a significant impact in the patient's health status. This manuscript aims to revise the peripheral immunological, endocrine, and intestinal microbiome changes induced by AAP consumption recommended in the clinical guidelines for schizophrenia and other psychiatric disorders.

show abstract

Section: Paliperidonementioning

confidence: 93%

Immunoendocrine Peripheral Effects Induced by Atypical Antipsychotics

et al. 2020

View full text Add to dashboard Cite

show abstract

“…A case report of hypoglycemia was excluded in one study because the patient had noninsulin-dependent diabetes mellitus and was taking risperidone concurrently with glyburide and sertraline [ 11 ]. Moreover, some studies have reported that risperidone induces hypoglycemia by increasing insulin secretion in nondiabetic patients with schizophrenia [ 12 , 13 ]. One of these reports indicated that a reduction in risperidone dose mitigated its effect of induced hypoglycemia.…”

Section: Introductionmentioning

confidence: 99%

“…Furthermore, a study reported that switching from olanzapine to risperidone for the treatment of schizophrenia exacerbated a patient’s diabetes mellitus and hyperglycemia and resulted in decreased blood glucose levels and increased insulin levels [ 14 ]. Evidence suggests an association between risperidone use and a reduced risk of abnormalities during glucose–insulin homeostasis [ 13 , 14 ]. However, some reports have indicated that risperidone is associated with hyperglycemia and exacerbates preexisting diabetes and hypertriglyceridemia in patients on antipsychotic therapy [ 15 , 16 , 17 ] and that its long-term use induces nonalcoholic fatty liver disease-associated visceral adiposity [ 18 ] as well as liver damage [ 19 ] in animal models.…”

Section: Introductionmentioning

confidence: 99%

Risperidone Exacerbates Glucose Intolerance, Nonalcoholic Fatty Liver Disease, and Renal Impairment in Obese Mice

Tsai

Hou

Mao

et al. 2021

IJMS

View full text Add to dashboard Cite

Risperidone, a second-generation antipsychotic drug used for schizophrenia treatment with less-severe side effects, has recently been applied in major depressive disorder treatment. The mechanism underlying risperidone-associated metabolic disturbances and liver and renal adverse effects warrants further exploration. This research explores how risperidone influences weight, glucose homeostasis, fatty liver scores, liver damage, and renal impairment in high-fat diet (HFD)-administered C57BL6/J mice. Compared with HFD control mice, risperidone-treated obese mice exhibited increases in body, liver, kidney, and retroperitoneal and epididymal fat pad weights, daily food efficiency, serum triglyceride, blood urea nitrogen, creatinine, hepatic triglyceride, and aspartate aminotransferase, and alanine aminotransferase levels, and hepatic fatty acid regulation marker expression. They also exhibited increased insulin resistance and glucose intolerance but decreased serum insulin levels, Akt phosphorylation, and glucose transporter 4 expression. Moreover, their fatty liver score and liver damage demonstrated considerable increases, corresponding to increases in sterol regulatory element-binding protein 1 mRNA, fatty acid-binding protein 4 mRNA, and patatin-like phospholipid domain containing protein 3 expression. Finally, these mice demonstrated renal impairment, associated with decreases in glutathione peroxidase, superoxide dismutase, and catalase levels. In conclusion, long-term administration of risperidone may exacerbate diabetes syndrome, nonalcoholic fatty liver disease, and kidney injury.

show abstract

“…To the best of our knowledge, there are no reports on clozapine‐induced hypoglycemia, but there are case reports of the development of hypoglycemia with other antipsychotics 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 (Table 1 ). Most patients develop hypoglycemia induced by second‐generation antipsychotics, with olanzapine and quetiapine being the most frequent.…”

Section: Discussionmentioning

confidence: 99%

“…To the best of our knowledge, there are no reports on clozapine-induced hypoglycemia, but there are case reports of the development of hypoglycemia with other antipsychotics [4][5][6][7][8][9][10][11][12][13] (Table 1). Most patients develop hypoglycemia induced by The treatment of impaired glucose tolerance includes diet, exercise, and oral hypoglycemic medications.…”

Section: Melkersson Et Al Suggested That the Putative Mechanism Of Cl...mentioning

confidence: 99%

Recurrent reactive hypoglycemia due to clozapine‐induced glucose intolerance: A case report

Kawai,

Watanabe,

Ebihara

et al. 2023

PCN Reports

View full text Add to dashboard Cite

BackgroundAlthough diabetes is one of the most common side effects of clozapine, a medication for the treatment of schizophrenia, to the best of our knowledge no study exists on clozapine‐induced glucose intolerance or hypoglycemia in patients with schizophrenia.Case PresentationWe report a case of schizophrenia with repeated reactive hypoglycemia due to abnormal glucose tolerance during clozapine treatment. During clozapine administration in patients with schizophrenia, it is necessary to monitor physical and psychiatric symptoms due to reactive hypoglycemia and hyperglycemia. If abnormal glucose tolerance is a concern, it should be promptly detected using blood or oral glucose tolerance tests.ConclusionEarly intervention for impaired glucose tolerance may prevent clozapine discontinuation due to diabetes or hyperglycemia.

show abstract

Paliperidone Induced Hypoglycemia by Increasing Insulin Secretion

Cited by 6 publications

References 11 publications

Immunoendocrine Peripheral Effects Induced by Atypical Antipsychotics

Immunoendocrine Peripheral Effects Induced by Atypical Antipsychotics

Risperidone Exacerbates Glucose Intolerance, Nonalcoholic Fatty Liver Disease, and Renal Impairment in Obese Mice

Recurrent reactive hypoglycemia due to clozapine‐induced glucose intolerance: A case report

Contact Info

Product

Resources

About